Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2443 | Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances Wiki | 0.38 |
| drug1485 | High-Concentration Essential Oil Wiki | 0.27 |
| drug2307 | Olfactory retraining Wiki | 0.27 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug541 | Brain MRI scan Wiki | 0.27 |
| drug378 | BAT2020 Wiki | 0.27 |
| drug3514 | Tranexamic acid tablets Wiki | 0.27 |
| drug1677 | Injection into olfactory cleft Wiki | 0.27 |
| drug2128 | NHANES smell and taste tests Wiki | 0.27 |
| drug2569 | Placebo/Control Wiki | 0.27 |
| drug2152 | Nasal Irrigation Wiki | 0.27 |
| drug568 | Budesonide Wiki | 0.27 |
| drug4013 | olfactory and gustatory tests Wiki | 0.27 |
| drug569 | Budesonide Nasal Wiki | 0.27 |
| drug2495 | Physiological serum Wiki | 0.27 |
| drug2314 | Omega-3 Fatty Acid Supplement Wiki | 0.27 |
| drug1394 | General Public cohort Wiki | 0.27 |
| drug3852 | corticosteroid nasal irrigation Wiki | 0.27 |
| drug3974 | mometasone furoate nasal spray Wiki | 0.27 |
| drug1900 | Low-Concentration Essential Oil Wiki | 0.27 |
| drug4109 | smell household Items Wiki | 0.27 |
| drug3676 | Vitamin D Wiki | 0.09 |
| drug2557 | Placebo oral tablet Wiki | 0.05 |
| drug2505 | Placebo Wiki | 0.02 |
Navigate: Correlations HPO
There are 14 clinical trials
Loss of sense of smell and taste has been anecdotally reported during the covid-19 epidemic. The study investigators wanted to describe the prevalence of olfactory and gustatory dysfunction and assess the factors associated with positive SARS-CoV-2 infection.
Description: Positive/negative according to RT-PCR assay
Measure: SARS-CoV-2 infection status Time: Day 0Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 0Description: Ability to smell 1.5ml air freshner on a 0-100 VAS scale
Measure: Ability to detect odor Time: Day 0Description: Ability to smell 1.5ml air freshner on a 0-100 VAS scale
Measure: Ability to detect odor Time: Six monthsDescription: Ability to taste a pinch of table salt on a 0-100 VAS scale
Measure: Ability to detect salty taste Time: Day 0Description: Ability to taste a pinch of table salt on a 0-100 VAS scale
Measure: Ability to detect salty taste Time: Six monthsDescription: Ability to taste a pinch of sugar on a 0-100 VAS scale
Measure: Ability to detect sweet taste Time: Day 0Description: Ability to taste a pinch of sugar on a 0-100 VAS scale
Measure: Ability to detect sweet taste Time: Six monthsDescription: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 7Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 14Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 30Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 60Description: % patients hospitalized
Measure: Severity of infection according to hospitalization rate Time: End of study (six months)Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Six monthsThe initial symptoms described in the first cases of COVID-19 were mainly fever and respiratory signs. Recently, there has been an increase in cases of hyposmia without associated nasal obstruction or rhinorrhea. Although we do not yet know the long-term consequences of COVID-19 on olfaction, there is evidence in the literature demonstrating that post-viral hyposmias are an important source of long-term olfactory disorders, impacting quality of life. Usually, the treatment of viral hyposmias is based on local and/or general corticosteroid treatment combined with saline nasal irrigation at the onset of signs. Because of the possible development of severe forms of the SARS-Cov-2 infection, the French Society of Otorhinolaryngology has advised against treatment by corticosteroid therapy and nasal irrigation. However, as the virus is present in the nasal fossae on average for 20 days, persistent hyposmia at 30 days would probably result from an inflammatory or neurological damage to the nasal slits or olfactory bulb. Local treatment with corticosteroids could then be instituted from 30 days after the onset of symptoms of COVID-19 without risk of dissemination. In persistent hyposmia other than chronic rhinosinusitis, the only treatment that has proven its efficacy is nasal irrigation associated with budesonide and olfactory rehabilitation. However, this drug does not have marketing authorisation in France for this indication.
Description: Percentage of patients with an improvement of more than 2 points on the ODORATEST score (5) after 30 days of treatment
Measure: Patient with more than 2 points on the ODORATEST Time: 30 daysThe study will be a randomized controlled trial, involving patients with hyposmia/anosmia of onset immediately after an upper respiratory viral illness, assigned to three distinct study arms. Nasal irrigations will be prescribed to all three groups (BID). In addition, one arm will receive a paper hand-out about post-viral anosmia with instructions to smell common household items (current care) and act as a control group. The second group will receive an essential oil retraining kit, whereas the third group will receive the same olfactory training kit and a prescription to use budesonide with the nasal irrigations. Olfactory scores will be tested at the enrollment, 3 months and at 6 months.
Description: Score from the Snap and Sniff Olfactory Test results
Measure: Change from Baseline Snap and Sniff Threshold Test at 3 months Time: 3 monthsDescription: Score from the Smell Identification test results.
Measure: Change from baseline Smell Identification Test (SIT) at 3 months Time: 3 monthsDescription: Score from the Snap and Sniff Olfactory Test results
Measure: Change from Baseline Snap and Sniff Threshold Test at 6 months Time: 6 monthsDescription: Score from the Smell Identification test results.
Measure: Change from baseline Smell Identification Test (SIT) at 6 months Time: 6 monthsDescription: Scores from the short version of the Questionnaire of Olfactory Disorders Negative Statements (QOD-NS)
Measure: Change from baseline QOD-NS at 3 months Time: 3 monthsDescription: Short Form 36 Health Survey scores
Measure: Change from baseline SF-36 health survey at 3 months Time: 3 monthsDescription: Scores from the short version of the Questionnaire of Olfactory Disorders Negative Statements (QOD-NS)
Measure: Change from baseline QOD-NS at 6 months Time: 6 monthsDescription: Short Form 36 Health Survey scores
Measure: Change from baseline SF-36 health survey at 6 months Time: 6 monthsDescription: Adherence comparison between participants post-CoVID 19 and patients post other viral infections.
Measure: Adherence to the Study Protocol Time: 6 monthsDescription: Compare the rate of recovery between post-COVID 19 patients and patients post other viral infections.
Measure: Recovery Time: 6 monthsThe FORECAST Study is an observational cohort study looking at two cohorts of patients presenting with COVID-19: a general public cohort, aiming to investigate if new loss or reduced sense of smell and/or taste are early signs of COVID-19 and a hospital cohort, which will investigate if taste/smell changes can predict the clinical course of a COVID-19 infection.
Description: percentage of people who report loss/reduced sense of smell or taste
Measure: Percentage of people reporting changes in smell/taste Time: 4 weeksDescription: to compare the case mortality rate in COVID-19 patients who experienced smell/taste changes compared to mortality in those who did not experience smell/taste changes.
Measure: mortality rate Time: through study completion, an average of 1 yearDescription: To identify the percentage of people who report changes in taste and/or smell before developing either fever or persistent cough who are positive for SARS-CoV-2 IgM and IgG
Measure: Percentage of people with change in smell/taste before other symptoms Time: 4 weeksDescription: To examine the proportion of other COVID-19 linked symptoms in people with smell and/or taste change who are positive positive for SARS-CoV-2 IgM and IgG who never develop fever and/or cough.
Measure: proportion of other COVID-19 linked symptoms in people with smell and/or taste change Time: 4 weeksDescription: To determine the percentage of people whose smell and/or taste symptoms persist for greater than 4 weeks in people who are positive for SARS-CoV-2 IgM and IgG
Measure: Percentage of people with persistent changes in smell and/or taste Time: 12 weeksDescription: To determine the percentage of patients who report loss/decrease in sense of smell and/or taste changes before or in the absence of other symptoms of COVID-19, who are admitted to hospital with COVID-19
Measure: Percentage of hospitalisation Time: 12 weeksDescription: To investigate whether loss/reduced sense of smell and/or taste are associated with the course of illness and outcomes in COVID-19
Measure: co-morbidities association Time: through study completion, an average of 1 yearDescription: Assessing the prevalence of previous loss/decrease in sense of smell and/or taste changes in patients admitted to secondary care with COVID-19 infection.
Measure: prevalence of changes in smell/taste Time: through study completion, an average of 1 yearDescription: Correlating the presence of loss/decrease in sense of smell and/or taste changes to clinical outcomes including case fatality rate.
Measure: clinical outcomes Time: through study completion, an average of 1 yearThe Malaysian COVID-19 Anosmia Study is a nationwide multicentre observational study to investigate the prevalence and characteristics of olfactory and gustatory/taste disturbances in COVID-19 infection in Malaysia, and to evaluate the predictive value of screening for these symptoms in COVID-19 infection. This study consists of two phases: the first phase is a cross-sectional study and the second phase is a case-control study. The case-control study is described here (the cross-sectional study is described in a separate ClinicalTrials.gov record).
Description: In the patient-reported online questionnaire, subjects will be asked regarding whether they experienced symptoms of olfactory and/or taste disturbances
Measure: Presence or absence of olfactory and taste disturbances in study participants Time: 2 weeks prior to answering questionnaire/ prior to diagnosis of COVID-19 infectionDescription: The relationship between case & control status and each exposure variable will be estimated by odds ratios and their 95% confidence intervals using conditional logistic regression models.
Measure: Adjusted odds ratio of olfactory & taste disturbances in COVID-19 infection Time: 2 weeks prior to answering questionnaire/ prior to diagnosis of COVID-19 infectionDescription: In the patient-reported online questionnaire, subjects will be asked regarding other symptoms they experienced when they were diagnosed with COVID-19/within the past 2 weeks of answering the questionnaire (e.g. headache, nasal congestion, fever, chills, cough, dyspnoea, gastrointestinal symptoms, eye & ear symptoms)
Measure: Clinical manifestations of study participants Time: 2 weeks prior to answering questionnaire/ prior to diagnosis of COVID-19 infectionDescription: In the patient-reported online questionnaire, subjects will be asked regarding their pre-existing health conditions (for example, obesity, diabetes, hypertension, cardiac conditions, previous head trauma, chronic rhinosinusitis, etc.)
Measure: Other pre-existing health conditions Time: BaselineDescription: PPV reflects the probability that the presence of olfactory and taste disturbances will have a positive diagnosis of COVID-19. This is derived from dividing the number of patients with olfactory & taste disturbances with COVID-19 infection over the total number of patients with olfactory and taste disturbances, and multiplying by 100%
Measure: Positive predictive value (PPV) of olfactory and taste disturbances in predicting diagnosis of COVID-19 infection Time: BaselineDescription: NPV reflects the probability that the absence of olfactory and taste disturbances will have a negative diagnosis of COVID-19. This is derived from dividing the number of patients without olfactory & taste disturbances and without COVID-19 infection over the total number of patients with no olfactory and taste disturbances, and multiplying by 100%
Measure: Negative predictive value (NPV) of olfactory and taste disturbances in predicting absence of COVID-19 infection Time: BaselineDescription: The percentage of true positives, i.e. the proportion of patients with olfactory and taste disorders with COVID-19 infection. This can be calculated by dividing the number of subjects with olfactory & taste disturbances who have COVID-19 infection with the number of patients with olfactory & taste disturbances, and multiplying by 100%
Measure: Sensitivity of olfactory and taste disturbances in predicting COVID-19 infection Time: BaselineDescription: The percentage of true negatives, i.e. the proportion of patients without olfactory and taste disorders who do not have COVID-19 infection. This can be calculated by dividing the number of subjects without olfactory & taste disturbances who do not have COVID-19 infection with the number of patients without olfactory & taste disturbances, and multiplying by 100%
Measure: Specificity of olfactory and taste disturbances in predicting COVID-19 infection Time: BaselineCOVID-19 has adversely affected the healthcare system across the world. The world was not prepared for global outbreak of infectious diseases. The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is enabling researchers worldwide to acquire a large amount of clinical data regarding coronavirus disease (COVID-19). The COVID-19 infection severely affects the respiratory system in the critical cases and results in mortalities. The affected people experience a dry cough, fever, breathing problems, diarrhea, muscle pain, and sore throat. Besides that, some of the evidence from Italy, South Korea, China, and Spain suggest that the COVID-19 cases also lose their senses of smell and taste resulting in alterations in those patients. The objective of this proposed study is to determine whether COVID-19 cases have Olfactory and gustatory dysfunctions as a hallmark indicator and can be used as diagnostic tools for the isolation of suspected people. Investigators are presenting a prospective proportional case-control study that is conducted to investigate the COVID-19 cases with anosmia and /or Ageusia in a university hospital in Riyadh, Saudi Arabia. The sample size of this case series would be 250 cases of suspected COVID-19 patients. The cases included in the study are analyzed prospectively to determine if the cases had a history of anosmia and /or Ageusia, and then tested for the alteration of these senses through a panel of standardized odors/taste strips. That is looked at statistically allowing us to confirm the proposed effectiveness of these tests as a diagnostic tool.
Description: to how extent alteration of smell and taste senses is related to covid19 status
Measure: correlation of anosmia and ageusia to covid19 positive patients Time: from 1/06/2020 to 31/12/2020Description: to determine the range of sense affection ranging from total loss to mild form
Measure: objective assessment of severity of smell and taste senses alterations in covid19 patients Time: from 1/06/2020 to 31/12/2020The Malaysian COVID-19 Anosmia Study is a nationwide multicentre observational study to investigate the prevalence and characteristics of olfactory and gustatory/taste disturbances in COVID-19 infection in Malaysia, and to evaluate the predictive value of screening for these symptoms in COVID-19 infection. This study consists of two phases: the first phase is a cross-sectional study and the second phase is a case-control study. The cross-sectional study is described here (the case-control study is described in a separate ClinicalTrials.gov record).
Description: In the patient-reported online questionnaire, subjects will be asked regarding whether they experienced symptoms of olfactory and/or taste disturbances
Measure: Presence or absence of olfactory and taste disturbances in COVID-19 patients Time: Within 2 weeks preceding the diagnosis of COVID-19 infectionDescription: Percentage of COVID-19 patients experiencing olfactory disturbances (anosmia or hyposmia)
Measure: Prevalence of olfactory disturbances in COVID-19 patients Time: Within 2 weeks preceding the diagnosis of COVID-19 infectionDescription: Percentage of COVID-19 patients experiencing taste disturbances
Measure: Prevalence of taste disturbances in COVID-19 patients Time: Within 2 weeks preceding the diagnosis of COVID-19 infectionDescription: In the patient-reported online questionnaire, subjects will be asked regarding other symptoms they experienced when they were diagnosed with COVID-19 (e.g. headache, nasal congestion, fever, chills, cough, dyspnoea, gastrointestinal symptoms, eye & ear symptoms)
Measure: Clinical manifestations of study participants Time: Within 2 weeks preceding the diagnosis of COVID-19 infectionDescription: In the patient-reported online questionnaire, subjects will be asked regarding their pre-existing health conditions (for example, obesity, diabetes, hypertension, cardiac conditions, previous head trauma, chronic rhinosinusitis, etc.)
Measure: Other pre-existing health conditions Time: Prior to diagnosis of COVID-19 infectionDescription: In the patient-reported online questionnaire, subjects will be asked to rate their sense of smell and taste before their diagnosis of COVID-19 infection
Measure: Rating of baseline sense of smell & taste in COVID-19 patients prior to diagnosis of their infection Time: Prior to 2 weeks preceding the diagnosis of COVID-19 infection (Baseline)Description: In the patient-reported online questionnaire, subjects will be asked to rate their sense of smell and taste at the time of diagnosis of COVID-19 infection
Measure: Rating of sense of smell & taste in COVID-19 patients at time of diagnosis of their infection Time: Within 2 weeks preceding the diagnosis of COVID-19 infectionDescription: In the patient-reported online questionnaire, subjects will be asked to rate their sense of smell and taste at the time of answering questionnaire survey
Measure: Rating of sense of smell & taste in COVID-19 patients at time of answering questionnaire survey Time: Up to 6 monthsThis randomized clinical trial will evaluate the benefit of platelet-rich plasma (PrP) in the treatment of olfactory dysfunction. PrP can be isolated from a patient's own blood and has been found in previous studies to have anti-inflammatory and pro-regenerative properties. It has been used across multiple specialties, such as Orthopedics, Facial Plastics, Dermatology, Neurology in injected form to treat a wide variety of tissues to encourage the body's inherent regenerative capacity. We have completed a pilot study here evaluating it's use in olfactory loss which demonstrated safety and also suggested efficacy. Therefore, we aim to assess the ability of PrP to improve olfactory function in patients with decreased sense of smell.
Description: Using Sniffin' Sticks olfactory testing pens to test smell
Measure: Smelling ability Time: 6 monthsTo date there is no brain imaging and olfactory data available in COVID-19 positive patients with anosmia. By describing the pathophysiological characteristics underlying the olfactory symptoms and clinical characteristics of COVID-19 infection, the study investigators wish to compare the MRI aspects obtained in COVID-19 patients with and without anosmia, in the absence of other underlying neurological disorders.
Description: MRI; Voxels
Measure: Brain regional homogeneity between COVID-19 patients with and without anosmia Time: Day 0Description: MRI; Voxels
Measure: Brain regional homogeneity between COVID-19 patients with and without anosmia Time: Month 3Description: MRI; Voxels
Measure: Topography of supra- or sub-tentorial lesions between COVID-19 patients with and without anosmia Time: Day 0Description: MRI; voxels, value between 0-1
Measure: Fractional anisotropy between COVID-19 patients with and without anosmia Time: Day 0Description: MRI; voxels, value between 0-1
Measure: Fractional anisotropy between COVID-19 patients with and without anosmia Time: Month 3Description: MRI; mm2/s
Measure: Mean diffusivity between COVID-19 patients with and without anosmia Time: Day 0Description: MRI; mm2/s
Measure: Mean diffusivity between COVID-19 patients with and without anosmia Time: Month 3Description: MRI; mm2/s
Measure: Radial diffusivity between COVID-19 patients with and without anosmia Time: Day 0Description: MRI; mm2/s
Measure: Radial diffusivity between COVID-19 patients with and without anosmia Time: Month 3Description: Four questions measured by 0-100 visual analogue scale: how do you rate the quality of your sense of smell/taste normally/today
Measure: Self-assessed olfactory and gustatory test Time: Day 0Description: Four questions measured by 0-100 visual analogue scale: how do you rate the quality of your sense of smell/taste normally/today
Measure: Self-assessed olfactory and gustatory test Time: Day 8Description: Four questions measured by 0-100 visual analogue scale: how do you rate the quality of your sense of smell/taste normally/today
Measure: Self-assessed olfactory and gustatory test Time: Month 1Description: Four questions measured by 0-100 visual analogue scale: how do you rate the quality of your sense of smell/taste normally/today
Measure: Self-assessed olfactory and gustatory test Time: Month 2Description: Ability to smell 1.5ml air freshner on a 0-100 VAS scale (cut-offs: strang (>80), moderate (40-80), attenuated (<40)
Measure: Ability to detect odor Time: Day 0Description: Patient asked to describe whether a pinch of sugar on their tongue taste sweet or salty
Measure: Ability to taste a pinch of sugar Time: Day 0Description: MRI: absence/presence
Measure: Presence of thrombotic and hemorrhagic lesions Time: Day 0Description: MRI: absence/presence
Measure: Presence of thrombotic and hemorrhagic lesions Time: Month 3Description: Short Ti Inversion Recovery (STIR); presence/absence
Measure: Presence of lesions with hyperintensity Time: Day 0Description: Short Ti Inversion Recovery (STIR); presence/absence
Measure: Presence of lesions with hyperintensity Time: Month 3Description: beta voxels
Measure: Projection network analysis of all patients Time: Day 0Description: beta voxels
Measure: Projection network analysis of all patients Time: Month 3Description: beta voxels
Measure: Blinded independent component analysis of all patients Time: Day 0Description: beta voxels
Measure: Blinded independent component analysis of all patients Time: Month 3Description: beta voxels
Measure: default mode network analysis of all patients Time: Day 0Description: beta voxels
Measure: default mode network analysis of all patients Time: Month 3Description: beta voxels
Measure: executive control network analysis of all patients Time: Day 0Description: beta voxels
Measure: executive control network analysis of all patients Time: Month 3As the COVID-19 pandemic spread around the world, anosmia and dysgeusia were quickly recognized as two of the key presenting symptoms. The probability of return of smell is related to severity of smell loss at presentation, but it appears that the loss of sense of smell and taste seems to persist in approximately 10% of the affected patients after 6 months. As a result of COVID-19, it is estimated that within the next 12 months > 150,000 Americans will suffer permanent loss of smell. The magnitude of this impairment on the health, safety, and quality of life is truly unprecedented and makes post-COVID olfactory disorder a major public health problem. Thus, there is a pressing need to identify effective treatments. The research questions are to determine the effects of steroid nasal saline lavage and olfactory training among adults with post-COVID olfactory dysfunction and identify confounders and modifiers of any observed effects. To answer the research question, the investigators propose a 2 x 2 factorial design blinded randomized clinical trial whereby 220 subjects with documented COVID-19 with anosmia/hyposmia of 12 weeks duration or longer from Missouri, Illinois, and Indiana will be recruited electronically from COVID patient advocacy sites, social media sites, and other internet sources. Enrolled subjects will be randomized to nasal saline lavage with topical budesonide or placebo to address the presumed role of inflammation in the olfactory cleft and each subject will also be randomized to olfactory training with patient-specific, high- or low-concentration essential oil scent to assess the role of olfactory training. Data will be analyzed in a blinded fashion to allow estimation of observed effect size for both anti-inflammatory and olfactory training. This innovative study will exploit the unique opportunities presented by COVID-19. The study will use a high-tech virtual "contactless" research strategy, including eConsent and digital mHealth techniques to obtain rapid answers to the research questions. The interventions are low-cost, readily available, and results of this study can be directly disseminated to the care of COVID-19 patients with anosmia.
Description: The University of Pennsylvania Smell Identification Test (UPSIT) (Sensonics, New Jersey)7 is the most widely accepted olfactory identification test in North America. The UPSIT consists of four 10-page booklets, with a total of 40 items. Subjects are asked to scratch each strip with a pencil to release the scents, detect the smell, and identify the smell from the four choice options. The UPSIT comes from a scoring rubric that identifies the normalcy benchmark based on age and gender. Normosmia is defined as ≥34 for males and ≥35 for females, and an increase of 4 points or more from baseline indicates a clinically meaningful improvement. UPSIT has high internal reliability across a wide range of populations.
Measure: University of Pennsylvania Smell Identification Test (UPSIT) Time: The within subject change in UPSIT between baseline and 12- and 24-week assessment time frame.Description: The Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS) was adapted from the original 52-item Questionnaire of Olfactory Disorders. This short-modified version is a validated 17-item questionnaire about quality of life and impairments related to olfactory dysfunction. The maximum score is 51, and higher values indicate worse quality of life or higher degree of impairment of normal daily activity. Mean scores in anosmics is 19; hyposmics is 8; and normosmics is 0. Prior studies used a cutoff score of 12.5 to reflect normal vs. abnormal scores.The minimum clinically important difference is 5.2.
Measure: Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS). Time: The within subject change in QOD-NS between baseline and assessment time frame.Description: The Global Rating of Smell is a single-item, global rating that asks: "Overall, please rate your current sense of smell? Excellent, Very Good, Good, Fair, Poor, Absent."
Measure: Global Rating of Smell. Time: 12 weeks - End of nasal lavage & olfactory training; 24 weeks - Follow-up (12 weeks after completion of lavage & training)Description: The Global Rating of Smell Change is a single-item, global rating that asks: "Compared to your sense of smell # weeks ago, how would you rate your change in smell since then? Much better, Somewhat better, Slightly better, Neither better nor worse, Slightly worse, Somewhat worse, or Much worse." The time frame ("#") will be changed to reflect the correct time since enrollment (i.e., 12, or 24 weeks).
Measure: Global Rating of Smell Change. Time: 12 weeks - End of olfactory training; 24 weeks - Follow-up (12 weeks after completion of lavage & training)This study is designed to investigate the acuity of olfactory dysfunction in COVID-19 positive patients in the United Kingdom. In particular defining severity with objective testing and determining if this has any predictive value on the outcome of the SARS CoV-2 infection. In addition, this study will strive to determine duration / natural history of olfactory dysfunction in these patients in respect to a positive SARS CoV-2 diagnosis. It should also demonstrate the impact of olfactory dysfunction on patient Quality of Life (QOL).
Description: I. Primary endpoint is olfactory function assessed using the UPSIT and classified as Anosmia; Mild, moderate, and severe microsomia. assessed at the time COVID-19 diagnosis (+1 week) or at the time of registration for in hospital patients
Measure: UPSIT scores Time: At time of diagnosis (+1 week ) post COVID 19 diagnosis or at time of recruitment into studyDescription: I. The changes in olfaction in patients with SARS CoV-2 infection over an initial 12 month period (at day 0, 1 month, 3 month, 6 month, 9 month and 12 month) using the UPSIT.
Measure: UPSIT scores Time: at day 0, 1 month, 3 month, 6 month, 9 month and 12 monthDescription: Quality of Life using the validated Questionnaire of Olfactory Disorders for English speakers (eQOD)
Measure: eQOD scores Time: at day 0, 1 month, 3 month, 6 month, 9 month and 12 monthDescription: Quality of Life using the validated SinoNasal Outcome Tool-22 (SNOT-22)
Measure: SNOT 22 scores Time: at day 0, 1 month, 3 month, 6 month, 9 month and 12 monthThe study aims to test the frequency of severe acute respiratory syndrome new corona virus SARS-CoV-2 or other respiratory viruses in patients presenting with anosmia or dysgeusia to Ain Shams University Hospitals, Cairo, Egypt.
Description: subjective questionnaire about smell and taste
Measure: Recovery from Anosmia Time: 3 weeksDescription: developing IgM/ IgG antibodies by rapid test
Measure: Seroconversion Time: 3 weeksDescription: developing other symptoms of COVID 19
Measure: COVID 19 Time: 3 weeksThe aim of this study is to evaluate the role of the topical corticosteroids nasal spray (mometasone furoate nasal spray) in improving anosmia in patients recovered from COVID-19 infection.
Description: The patient will report the degree of anosmia subjectively with score on a scale from 0 to 10 (0 means total loss of smell and 10 refers to completely normal smell sensation).
Measure: improvement of olfaction Time: 3 weeksTo capture the natural history of COVID-19 associated olfactory dysfunction as measured by two patient reported outcome measures (SNOT-22, QOD-NS) and a 6-week BSIT with a comparison to an intervention arm receiving daily omega-3 supplements.
Description: Brief Smell Identification Test (BSIT) is a 12-item instrument, full range score from 0 to 12, higher score indicates better olfactory performances.
Measure: Brief Smell Identification Test (BSIT) Time: Week 0Description: Brief Smell Identification Test (BSIT) is a 12-item instrument, full range score from 0 to 12, higher score indicates better olfactory performances.
Measure: Brief Smell Identification Test (BSIT) Time: 6 weeks after beginning to take supplementsDescription: The modified Brief Questionnaire of Olfactory Dysfunction - Negative Statements (QOD-NS) survey is a 17-item instrument, each item graded on a scale from 0 to 3, with total scale range from 0 to 51. Higher score indicates better olfactory-specific quality of life (QOL).
Measure: Modified Brief Questionnaire of Olfactory Dysfunction (mQOD-NS) Time: 1 week after softgel initiationDescription: The modified Brief Questionnaire of Olfactory Dysfunction - Negative Statements (QOD-NS) survey is a 17-item instrument, each item graded on a scale from 0 to 3, with total scale range from 0 to 51. Higher score indicates better olfactory-specific quality of life (QOL).
Measure: Modified Brief Questionnaire of Olfactory Dysfunction (mQOD-NS) Time: 2 weeks after softgel initiationDescription: The modified Brief Questionnaire of Olfactory Dysfunction - Negative Statements (QOD-NS) survey is a 17-item instrument, each item graded on a scale from 0 to 3, with total scale range from 0 to 51. Higher score indicates better olfactory-specific quality of life (QOL).
Measure: Modified Brief Questionnaire of Olfactory Dysfunction (mQOD-NS) Time: 4 weeks after softgel initiationDescription: The modified Brief Questionnaire of Olfactory Dysfunction - Negative Statements (QOD-NS) survey is a 17-item instrument, each item graded on a scale from 0 to 3, with total scale range from 0 to 51. Higher score indicates better olfactory-specific quality of life (QOL).
Measure: Modified Brief Questionnaire of Olfactory Dysfunction (mQOD-NS) Time: 6 weeks after softgel initiationDescription: Sino-Nasal Outcome Test (SNOT-22) is a 22-item instrument, total scale range from 0 to 110, higher score indicates more severe QOL impact.
Measure: Sinonasal Outcomes Test (SNOT-22) Time: 1 week after softgel initiationDescription: Sino-Nasal Outcome Test (SNOT-22) is a 22-item instrument, total scale range from 0 to 110, higher score indicates more severe QOL impact.
Measure: Sinonasal Outcomes Test (SNOT-22) Time: 2 weeks after softgel initiationDescription: Sino-Nasal Outcome Test (SNOT-22) is a 22-item instrument, total scale range from 0 to 110, higher score indicates more severe QOL impact.
Measure: Sinonasal Outcomes Test (SNOT-22) Time: 4 weeks after softgel initiationDescription: Sino-Nasal Outcome Test (SNOT-22) is a 22-item instrument, total scale range from 0 to 110, higher score indicates more severe QOL impact.
Measure: Sinonasal Outcomes Test (SNOT-22) Time: 6 weeks after softgel initiationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports